Epitopea doses first patient in UK ovarian cancer vaccine trial
Epitopea has begun a Phase 1/1b clinical trial for its RNA-based cancer vaccine, CryptiVax-1001, in the UK. The study targets women with advanced high-grade serous ovarian cancer to assess safety and immune response.
Why it matters
This trial addresses a significant treatment gap for patients with aggressive ovarian cancer who have limited options after initial chemotherapy.
Cancer Tech & devices Researcher / academic
The Phase 1/1b study will enrol up to 30 women with advanced high-grade serous ovarian cancer (HGSOC) at up to 10 clinical centres across the UK.
Researchers will assess the vaccine’s safety, tolerability and ability to trigger an immune response, alongside early signs of clinical activity.
The trial is being led by professor Susana Banerjee, consultant medical oncologist and research lead for the Gynaecology Unit at The Royal Marsden NHS Foundation Trust and professor in women’s cancers at The Institute of Cancer Research, London.
Banerjee said: “It is exciting to offer patients the option of the OVACT trial and I am delighted that we are underway with the first patient treated.
“The CryptiVax™-1001 vaccine has the potential to meaningfully extend remission for women where currently available maintenance therapies deliver limited durable benefit.”
Also covering this story
One other newsroom covered this event. We read that version too.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in